Citeline, a Norstella company
News. Context. Impact.
In-depth journalism and analysis of the pharma, biotech, medtech, and consumer health industries.
Latest News & Analysis
A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.
The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.
The Oncologic Drugs Advisory Committee voted 5-4 that the overall benefit-risk of UGN-102 is not favorable in patients with recurrent low grade, intermediate-risk, non-muscle invasive bladder cancer and also divided on whether randomized trials should be required for future development programs.
The FDA is not currently signaling that stringent rules for the process will be relaxed, but the agency's change in approach is notable.
Spotlight On Tariffs
The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.
Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.
Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.
As the US biosimilars market moves into its second decade, urgent changes are needed at the FDA if biosimilars are to meet their full potential, according to Biosimilars Forum chief executive Julie Reed.
Changes At The FDA
The FDA may have violated laws and regulations along with many norms in how it released its planned changes for COVID-19 vaccine approvals.
US FDA Commissioner Martin Makary’s call for placebo-controlled trials to confirm the efficacy of COVID-19 boosters is drawing a lot of criticism, but former Commissioner Robert Califf also supported the idea.
Deputy FDA Commissioner Grace Graham acknowledged the importance of user fees, while also calling for restructuring. She also said part of MAHA's mission is to reexamine uses of drugs not supported by data.
Pink Sheet sister publication In Vivo spoke to the former FDA commissioner about the recent layoffs and their impact on vaccine and other product development.
Explore Our Award-Winning Reporting
Immerse yourself in comprehensive global coverage, delivering unbiased, meticulously researched, and context-rich insights.

Regulatory & Policy
Essential updates and comprehensive coverage of industry regulations and emerging policy trends.

Commercial Insights
In-depth analysis of the global biopharma industry, offering news that goes beyond the headlines.

Executive Perspectives
Exclusive interviews, expert opinion, and critical insights tailored for life science decision-makers.

Medical Technology
Contextualized reporting on medtech advancements, market dynamics, industry data, and expert insights.

Off-Patent Medicines
Unrivalled news and analysis of the global generic, biosimilars and value-added medicines industries.

Health & Wellness
Your primary source for impactful news and insights in the health, beauty, and wellness industries.
Valuable Insights, Your Way

Engaging Articles
Engaging Articles
Quick to read yet rich in insight, our articles cover a diverse range of topics, delivering sharp, comprehensive analysis in every piece.

Contextualized News
Contextualized News
Go beyond the headlines with our in-depth news coverage, offering background and analysis to ensure you're fully informed on global events.

Future Trends Analysis
Future Trends Analysis
Discover emerging trends and innovative ideas with our forward-thinking thought-leadership providing actionable insights and visionary perspectives.

Thought-Provoking Podcasts
Thought-Provoking Podcasts
Listen to expert-led discussions and analysis through our engaging podcasts, designed to inform and inspire—whenever and wherever you are.

Timely Features
Timely Features
Stay up-to-date with our regularly updated features, delivering the latest trends, insights, and developments as they unfold.

Exclusive Conference Coverage
Exclusive Conference Coverage
Get insider access to major industry events with our detailed conference coverage, bringing you the latest insights from top leaders and innovators.
Unmatched Industry Coverage Year After Year
Access the full spectrum of our daily insights and in-depth reporting, delivering timely, actionable intelligence when it matters most.
7,000+In-Depth Articles
Expert insights delivered throughout the year500+Executive Interviews
Exclusive perspectives from industry leaders2,000+In-Depth Analyses
Deep dives into critical issues and trends500+Interactive Media
Engaging visual, audio and dynamic contentOur Expertise at a Glance
Discover how our dedicated team delivers unparalleled insights through rigorous research and expert analysis.


60+ Respected Journalists
Our team of over 60 trusted journalists operates across the US, Canada, UK, and Asia, delivering multilingual content.

Human Intelligence Filter
Local teams meticulously review industry news, filtering out 50-90% of the noise to highlight key events.

In-Person Meeting Coverage
Our journalists attend key events both in person and virtually, ensuring comprehensive coverage.

Thorough Research
We analyze regulatory and policy changes, check internal data, consult in-house analysts, review sell-side reports, and interview multiple sources.

Expert Interviews
We engage with company executives, clinical/medical KOLs, regulatory agencies, patient advocacy groups, payer organizations, lawyers, and other experts.

Premium News with Context
Our premium news includes in-depth analysis, insightful interviews, and comprehensive data.
In-Depth Analysis Powered by Citeline Data
Our global journalists leverage Citeline’s advanced analytics platforms to perform comprehensive data analysis and uncover valuable insights.

- Industry-Leading Market Analysis Tools: Comprehensive commercial, clinical, and regulatory insights.
- Real-Time Data Trends: Up-to-the-minute data for the latest industry developments.
- AI-Driven Solutions: Innovative technology accelerating drug development and delivery to patients.
- Custom Insights with Ask-the-Analyst: Tailored answers and analysis to address your specific questions.
These powerful tools deliver a wealth of information—from detailed industry reports to real-time data trends—enabling reporting that sets us apart from the rest.
Expert Analysis Across The Decades
With a rich history and commitment to excellence our seasoned journalists have consistently provided crucial industry insights, reflecting years of dedicated expertise.

Generics Bulletin
News and Expert Analysis on Generics and Biosimilars
In Vivo
Strategic Analysis for Medtech and Pharma Leaders
HBW Insight
News and Expert Analysis on the Healthcare Industry
Medtech Insight
News and Expert Analysis for Medtech Decision Makers
Scrip
Pharma News and Expert Analysis for Commercial Decision Makers
Pink Sheet
News and Expert Analysis on Pharma Policy and Regulation
US FDA
Beginnings of
today's FDA
Meet The Team

Karen Coleman
Executive Director,
News and Insights

Ian Haydock
Editor-in-Chief,
APAC

Nielsen Hobbs
Editor-in-Chief,
Pink Sheet

Eleanor Malone
Editor-in-Chief,
Commercial Insights

Andrea Charles
Vice President
Custom Content